AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03117881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DirectCAM
Description: The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
Study NCT03117881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleCAM
Description: The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
Study NCT03117881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rDirectCAM
Description: The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
Study NCT03973333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-C103C
Description: Weekly IV infusions
Study NCT00841607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticojejunostomy vs pancreaticogastrostomy
Study NCT00841607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy vs pancreaticogastrostomy
Study NCT03973333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV infusions every 3 weeks
Study NCT03973333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-C103C
Description: Weekly subcutaneous Injection
Study NCT02967809 — intervention group
Intervention type: DEVICE
Intervention: echography
Description: cardiac and pulmonary echography
Study NCT00635570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-cyclen Lo
Description: Low dose oral contraceptive
Study NCT00635570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Contraceptive vaginal ring
Study NCT02176356 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
Study NCT02176356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost ophthalmic solution 0.03%
Description: bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
Study NCT02176356 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® ULTRA XC
Description: JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
Study NCT02176356 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® ULTRA PLUS XC
Description: JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
Study NCT02176356 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLUMA® XC
Description: JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
Study NCT00306956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: offer a pacifier
Description: To offer a pacifier to normal newborn infants at 15 days of age
Study NCT00306956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: offer a pacifier
Description: To offer a pacifier to normal newborn infants at 15 days of age
Study NCT03583411 — intervention group
Intervention type: OTHER
Intervention: Epidemiological data collection
Description: To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
Study NCT03876002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PBR06
Description: Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
Study NCT02450617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional individual treatment
Description: Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
Study NCT02450617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional individual treatment
Description: Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
Study NCT02450617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment for PTSD
Description: 20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
Study NCT02450617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stabilizing group treatment for Dissociative disorders
Description: 20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
Study NCT00157690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg 1x weekly for 12 months
Study NCT00157690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 70 mg 1 x weekly for 12 months
Study NCT02711813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB08
Description: biologic
Study NCT02711813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03426553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Riboflavin+UV RBC
Description: 35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
Study NCT03426553 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: irradiated RBC
Description: 35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
Study NCT01330992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocular light or darkness exposure
Description: Ocular light or darkness exposure
Study NCT01504009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle training
Description: 12 weeks of strength training 2-3 times/week
Study NCT04039555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 intimate
Description: Two sessions with CO2 intimate laser for vaginal symptoms treatment
Study NCT04039555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium-yag
Description: Two sessions with Erbium-yag laser for vaginal symptoms treatment
Study NCT04039555 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO2 intimate or Erbium-yag
Description: Two sessions of one of the two lasers with no therapeuthical energy
Study NCT00961896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo cream
Study NCT00961896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225 0.25%
Study NCT00961896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225 0.75%
Study NCT02591706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIS Implants
Description: The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
Study NCT02591706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIS Implants
Description: The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
Study NCT04085705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PATCH test
Description: The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
Study NCT03632226 — intervention group
Intervention type: DRUG
Intervention: 18F-OGA-1
Study NCT00908427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photoselective vaporization prostatectomy (PVP)
Description: PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
Study NCT02738957 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prenatal Counseling Group
Description: Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models.
Study NCT04047771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
Study NCT01436968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aglatimagene besadenovec + valacyclovir
Description: Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
Study NCT01436968 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + valacyclovir
Description: Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
Study NCT02503982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prophylactic Valganciclovir
Description: The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
Study NCT01585818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) intervention arm
Description: The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
Study NCT01585818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet Intervention
Description: The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
Study NCT02514577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Topical lotion
Study NCT02514577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-122 Vehicle Lotion
Description: Topical lotion. No active ingredient.
Study NCT03209245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purethal Mites
Description: perennial allergren specific immunotherapy during 24 months
Study NCT03209245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: perrenial injection wich were administered in same protocol as Purethal
Study NCT03209245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: monitoring of allergen specific IgE
Description: measurement the serum specific IgE at the start and at the end of trial
Study NCT03209245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: monitoring of allergen specific IgE
Description: measurement the serum specific IgE at the start and at the end of trial
Study NCT03209245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: monitoring of allergen specific IgG4
Description: measurement the serum specific IgG4 at the start and at the end of trial
Study NCT03209245 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: monitoring of allergen specific IgG4
Description: measurement the serum specific IgG4 at the start and at the end of trial
Study NCT05140707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
Study NCT01015378 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopid sigmoid resection
Description: A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
Study NCT00908427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of the prostate
Description: Standard transurethral resection of the prostate using electrocautery loop
Study NCT02314754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol 24-48 hours later
Description: 200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
Study NCT01964339 — intervention group
Intervention type: OTHER
Intervention: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
Description: Venous blood gas, basic metabolic panel, PSG variable data collection.
Study NCT01964339 — intervention group
Intervention type: OTHER
Intervention: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
Description: Arterial blood gas, basic metabolic panel, PSG variable data collection
Study NCT02684955 — intervention group
Intervention type: DEVICE
Intervention: Cerebral spectroscopy
Description: Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
Study NCT02684955 — intervention group
Intervention type: DEVICE
Intervention: Pupillometry
Description: The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
Study NCT03184597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HLA screening before commencing aromatic AEDs
Description: When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
Study NCT02622256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health System: HTN Intervention
Description: Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team \& may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
Study NCT02517528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet
Study NCT02517528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet
Study NCT02517528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet
Study NCT02986750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo Eye Drops
Description: Manufacturer: Laboratoires Thea, France
Study NCT02986750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optive Eye Drops
Description: Manufacturer: Allergan Pharmaceuticals, Ireland
Study NCT02986750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Eye Drops
Description: Manufacturer: Alcon Pharma GmbH
Study NCT04315129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Smart Catheter Biosensor
Description: A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
Study NCT03087994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional guidance intervention
Description: participants in this group will attend 12 meeting of nutritional guidance
Study NCT03087994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional guidance intervention
Description: Participants in this group will only receive nutrition guidance once during the study
Study NCT02097849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
Study NCT02097849 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tetanus diphtheria toxoids vaccine
Description: Administered as described in the treatment arm
Study NCT02097849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus diphtheria toxoids vaccine
Description: Administered as described in the treatment arm
Study NCT02097849 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Administered as described in the treatment arm
Study NCT02097849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Administered as described in the treatment arm
Study NCT02097849 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)
Description: Administered as described in the treatment arm